Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals

PURPOSE: The response rate of head and neck squamous cell carcinoma (HNSCC) patients to cetuximab therapy is only 15–20%, despite frequent EGFR overexpression. Since immunosuppression is common in HNSCC, we hypothesized that adding a pro-inflammatory TLR8 agonist to cetuximab therapy might result in...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Clin Cancer Res
Hoofdauteurs: Shayan, Gulidanna, Kansy, Benjamin A., Gibson, Sandra P., Srivastava, Raghvendra M., Bryan, James Kyle, Bauman, Julie E., Ohr, James, Kim, Seungwon, Duvvuri, Umamaheswar, Clump, David A., Heron, Dwight E., Johnson, Jonas T., Hershberg, Robert M., Ferris, Robert L.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2017
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5754237/
https://ncbi.nlm.nih.gov/pubmed/29061643
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-0357
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items